Literature DB >> 11255426

Hormone replacement therapy and cognition: systematic review and meta-analysis.

E S LeBlanc1, J Janowsky, B K Chan, H D Nelson.   

Abstract

CONTEXT: Some observational data suggest that hormone replacement therapy (HRT) may reduce the risk of cognitive decline and dementia but results have been conflicting.
OBJECTIVE: To review and evaluate studies of HRT for preventing cognitive decline and dementia in healthy postmenopausal women. DATA SOURCES: Studies with English-language abstracts identified in MEDLINE (1966-August 2000), HealthSTAR (1975-August 2000, PsychINFO (1984-August 2000); Cochrane Library databases; and articles listed in reference lists of key articles. STUDY SELECTION: Randomized controlled trials and cohort studies were reviewed for the effects of HRT on cognitive decline; cohort and case-control studies were reviewed for dementia risk. No randomized controlled trials regarding dementia risk were identified. DATA EXTRACTION: Twenty-nine studies met inclusion criteria and were rated. Two reviewers rated study quality independently and 100% agreement was reached on Jadad scores and 80% agreement was reached on US Preventive Services Task Force quality scores. A final score was reached through consensus if reviewers disagreed. DATA SYNTHESIS: Studies of cognition were not combined quantitatively because of heterogeneous study design. Women symptomatic from menopause had improvements in verbal memory, vigilance, reasoning, and motor speed, but no enhancement of other cognitive functions. Generally, no benefits were observed in asymptomatic women. A meta-analysis of observational studies suggested that HRT was associated with a decreased risk of dementia (summary odds ratio, 0.66; 95% confidence interval, 0.53-0.82). However, possible biases and lack of control for potential confounders limit interpretation of these studies. Studies did not contain enough information to assess adequately the effects of progestin use, various estrogen preparations or doses, or duration of therapy.
CONCLUSIONS: In women with menopausal symptoms, HRT may have specific cognitive effects, and future studies should target these effects. The meta-analysis found a decreased risk of dementia in HRT users but most studies had important methodological limitations.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11255426     DOI: 10.1001/jama.285.11.1489

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  118 in total

Review 1.  Prevention of Alzheimer's disease: where we stand.

Authors:  Mary Sano
Journal:  Curr Neurol Neurosci Rep       Date:  2002-09       Impact factor: 5.081

Review 2.  The role of ovarian hormones in preserving cognition in aging.

Authors:  Jeri S Janowsky
Journal:  Curr Psychiatry Rep       Date:  2002-12       Impact factor: 5.285

Review 3.  Impact of estrogen therapy on Alzheimer's disease: a fork in the road?

Authors:  Roberta D Brinton
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

4.  [Evidence based basis of decision making for or against a postmenopausal hormone treatment].

Authors:  Eva Rásky
Journal:  Wien Klin Wochenschr       Date:  2004-07-31       Impact factor: 1.704

Review 5.  Normal genetic variation, cognition, and aging.

Authors:  P M Greenwood; Raja Parasuraman
Journal:  Behav Cogn Neurosci Rev       Date:  2003-12

6.  Estrogen treatment impairs cognitive performance after psychosocial stress and monoamine depletion in postmenopausal women.

Authors:  Paul A Newhouse; Julie Dumas; Heather Wilkins; Emily Coderre; Cynthia K Sites; Magdalena Naylor; Chawki Benkelfat; Simon N Young
Journal:  Menopause       Date:  2010-07       Impact factor: 2.953

7.  Sex differences in visuospatial abilities persist during induced hypogonadism.

Authors:  Gioia M Guerrieri; Paul G Wakim; P A Keenan; Linda A Schenkel; Kate Berlin; Carolyn J Gibson; David R Rubinow; Peter J Schmidt
Journal:  Neuropsychologia       Date:  2015-12-21       Impact factor: 3.139

8.  Bridging the Translation Gap: From Dementia Risk Assessment to Advice on Risk Reduction.

Authors:  Kaarin J Anstey; Ranmalee Eramudugolla; Diane E Hosking; Nicola T Lautenschlager; Roger A Dixon
Journal:  J Prev Alzheimers Dis       Date:  2015

Review 9.  Postmenopausal hormone therapy is not associated with risk of all-cause dementia and Alzheimer's disease.

Authors:  Jacqueline O'Brien; John W Jackson; Francine Grodstein; Deborah Blacker; Jennifer Weuve
Journal:  Epidemiol Rev       Date:  2013-09-15       Impact factor: 6.222

Review 10.  The Potential of Gonadal Hormone Signalling Pathways as Therapeutics for Dementia.

Authors:  X Du; R A Hill
Journal:  J Mol Neurosci       Date:  2016-08-15       Impact factor: 3.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.